Short answer
ARVINAS, INC. (ARVN) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $42M (down 59.1% year over year) with net income of −$35M.
Q3 2025 key financials · XBRL
- Revenue
- $42M
- −59.1% YoY · +87.1% QoQ
- Net income
- −$35M
- +28.7% YoY · +42.6% QoQ
- Operating margin
- -104.5%
- EPS (diluted)
- −$0.48
- +29.4% YoY · +42.9% QoQ
Source: XBRL data from the ARVINAS, INC. (ARVN) Q3 2025 10-Q on SEC EDGAR. USD.
ARVINAS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New operational risk: workforce reduction of ~48% in 2025 may disrupt clinical trials, commercialization, and increase attrition beyond planned staff cuts
- Regulatory risk: FDA workforce cuts by 3,500 employees and budget uncertainties may delay regulatory submissions and approvals, disrupting product development
- Financial risk: cash, equivalents, and marketable securities $787.6M as of Sept 30, 2025, expected to fund operations into H2 2028 but subject to change based on clinical trial progress
- Competitive risk: management transitions, including CEO and research head retirements in 2025, may disrupt operations and employee retention impacting near-term performance
- Legal/compliance risk: prolonged 2025 U.S. government shutdown limits FDA's ability to accept submissions requiring fee payment, delaying regulatory reviews
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARVINAS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.